Global Cell Penetrating Peptide Market Forecast Report to 2030, Featuring Biosynth, Creative Peptides, Cupid Peptide, Alta Bioscience, AnaSpec, Peptomyc, PolyPeptide, Bachem & Sarepta Therapeutics

DUBLIN, Feb. 5, 2024 /PRNewswire/ -- The "Global Cell Penetrating Peptide Market Size, Share & Trends Analysis Report By End-use, By Application (Drug Delivery, Gene Delivery, Diagnostics, Molecular Imaging, and Others), By Type, By Regional Outlook and Forecast, 2023 - 2030" report has been added to  ResearchAndMarkets.com's offering.

The latest comprehensive analysis of the Global Cell Penetrating Peptide Market reveals that the industry is poised for significant growth, projecting a market valuation of $2.7 billion by the year 2030. The report underscores an impressive compound annual growth rate (CAGR) of 10.5% throughout the forecast period from 2023 to 2030.

The detailed market analysis brings to light the rapidly evolving landscape of Cell Penetrating Peptides (CPPs) and their increasing application across various segments including drug delivery, gene delivery, diagnostics, and molecular imaging. Of particular interest is the surge in demand for Synthetic CPPs, which dominated the market share in 2022, attributing to its greater stability and efficacy in drug development.

Undergoing an in-depth End-Use Analysis, the report spotlights the segment of pharmaceutical and biotechnology companies as the leading revenue contributor in the past year. This sector is anticipated to maintain its dominance and experience robust growth in line with the burgeoning trends of personalized medicine and targeted therapies facilitated by CPPs.

In its Application Analysis, the publication illustrates the dynamic growth of the gene delivery segment, backed by cutting-edge advancements in gene therapy. Its integral role in enhancing genetic disease treatment cements the segment's substantial contribution to the industry's overall growth.

The study also sheds light on the regional market landscapes, with the European market capturing a significant share in 2022. Investments in biotechnology within the region have notably fostered the progression of CPP-based research and product development, indicating a lucrative trajectory for the local industry.

Critical market insights are provided by type segmentation, revealing a keen focus on synthetic, protein-derived, and chimeric CPPs. The relevance and impact of each type are thoroughly examined in relation to their organizational applications and projected market share towards the end of the forecast period.

Market Challenges and Advancements

• Diverse cellular uptake mechanisms present challenges in studying CPP entry into cells, potentially impacting demand.
• The pandemic has placed unforeseen stress on the market, with research efforts being diverted to focus on COVID-19.
• Investments in drug delivery technologies and therapeutic applications of CPPs signal continuous growth for the market.

The report delineates a complex yet progressive market environment, underlined by both innate challenges and the untapped potential of CPPs in modern medicine. This foundational research is poised to serve as a critical tool for industry stakeholders navigating the CPP market's expansive terrain.

The complete findings and strategic recommendations of this research are now accessible, providing stakeholders with in-depth insights into the multifaceted global cell-penetrating peptide market and its anticipated proliferation in the coming years.

Market Report Segmentation

By End-use

• Pharmaceutical and Biotechnology Companies
• Contract Research Organization (CROs)
• Hospitals & Clinics
• Others

By Application

• Drug Delivery
• Gene Delivery
• Diagnostics
• Molecular Imaging
• Others

By Type

• Synthetic CPPs
• Protein-derived CPPs
• Chimeric CPPs

Companies Profiled

• Biosynth Ltd
• Creative Peptides
• Cupid Peptide Company Limited
• Alta Bioscience Ltd
• AnaSpec Inc. (Kaneka Eurogentec S.A.) (Kaneka Corporation)
• Peptomyc SL
• PolyPeptide Group AG
• Bachem Holding AG (Ingro Finanz AG)
• Sarepta Therapeutics, Inc.
• Revance Therapeutics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/uzgh5n

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected] 
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets